Anuh Pharma Ltd Stock Price Today (NSE: ANUHPHR)
Fundamental Score
Anuh Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Anuh Pharma Ltd share price today is ₹67.00, down 2.77% on NSE/BSE as of 30 March 2026. Anuh Pharma Ltd (ANUHPHR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹801.50 (Cr). The 52-week high for ANUHPHR share price is ₹114.90 and the 52-week low is ₹69.27. At a P/E ratio of 20.71x, ANUHPHR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.41% and a debt-to-equity ratio of 0.00.
Anuh Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Anuh Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Anuh Pharma Share Price Analysis: Navigating the Generics Landscape
The pharmaceutical industry is currently experiencing a significant shift driven by increasing generic drug adoption globally and a focus on API (Active Pharmaceutical Ingredient) manufacturing. Understanding this macro trend is crucial when analyzing individual companies. This financial analysis focuses on Anuh Pharma share price, currently trading at ₹79.30, and aims to provide insights into the company's relative position within the competitive pharmaceutical landscape.
Anuh Pharma's current Price-to-Earnings (PE) ratio stands at 20.71. This valuation metric reflects investor expectations regarding future earnings growth. To properly assess this, we need to benchmark it against its peers. For instance, comparing Anuh Pharma Ltd with peers like
Mankind Pharma Ltd highlights differences in perceived management quality and growth prospects. Mankind Pharma, often commanding a premium PE, may reflect a market perception of stronger brand recognition, efficient distribution networks, or a more aggressive expansion strategy.A key indicator of a company's efficiency and profitability is its Return on Capital Employed (ROCE). Anuh Pharma’s ROCE of 17.24% suggests that the company is generating a reasonable return on its invested capital. This impacts the company's "moat" or competitive advantage. A consistently high ROCE indicates that Anuh Pharma has some advantages in its operations, such as efficient cost management, specialized product offerings, or favorable market access, allowing it to generate better returns than its peers. However, sustaining this ROCE in a competitive environment is critical.
In conclusion, this analysis provides an observational overview of Anuh Pharma's financial standing based on publicly available data. The current share price reflects a combination of market sentiment, earnings expectations, and the company's ability to generate returns. This analysis is an extract from a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anuh Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ANUHPHR across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (17.24%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 20.71 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (16.60% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (25.58% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (86.70x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹79.91 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (71.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Profit Decline Concern (-49.40%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Anuh Pharma Ltd Financial Statements
Comprehensive financial data for Anuh Pharma Ltd including income statement, balance sheet and cash flow
About ANUHPHR (Anuh Pharma Ltd)
Anuh Pharma Ltd is a dynamic pharmaceutical manufacturer deeply rooted in the Indian landscape. With a strong focus on bulk drug and chemical production, the company serves as a cr...itical link in the pharmaceutical supply chain. Anuh Pharma boasts a diverse portfolio of active pharmaceutical ingredients (APIs), meticulously crafted to meet the rigorous demands of the global healthcare industry. Their offerings encompass a spectrum of therapeutic categories, reflecting their commitment to addressing a wide range of medical needs. From essential treatments for infectious diseases to innovative solutions for chronic conditions, Anuh Pharma strives to provide high-quality ingredients that contribute to the development of life-enhancing medications. Their strength lies in their understanding of complex chemical processes and their adherence to strict regulatory standards. Beyond its core API offerings, Anuh Pharma demonstrates a commitment to continuous innovation. The company is actively involved in the development of specialized products, including niche chemicals and intermediates, further solidifying its position as a versatile partner within the pharmaceutical sector. This proactive approach to product development allows Anuh Pharma to adapt to the evolving needs of the market and cater to the specific requirements of its clientele. Their expertise extends to several therapeutic areas, reflecting a comprehensive approach to healthcare solutions. This adaptability and dedication to innovation allows Anuh Pharma to make significant strides and add value to its partners. Anuh Pharma's business model revolves around providing reliable and cost-effective solutions to pharmaceutical companies worldwide. Their commitment to quality, consistency, and timely delivery has earned them a reputation as a trusted supplier. By maintaining stringent quality control measures throughout the manufacturing process, Anuh Pharma ensures that its products meet the highest industry standards. This dedication to excellence has fostered long-term relationships with key players in the pharmaceutical industry. Anuh Pharma continues to invest in research and development, as well as, technology, in order to build on their business model and ensure customer satisfaction.
Company Details
Key Leadership
Corporate Events
ANUHPHR Share Price: Frequently Asked Questions
What is the current share price of Anuh Pharma Ltd (ANUHPHR)?
As of 30 Mar 2026, 12:07 pm IST, Anuh Pharma Ltd share price is ₹67.00. The ANUHPHR stock has a market capitalisation of ₹801.50 (Cr) on NSE/BSE.
Is ANUHPHR share price Overvalued or Undervalued?
ANUHPHR share price is currently trading at a P/E ratio of 20.71x, compared to the industry average of 31.77x. Based on this relative valuation, the Anuh Pharma Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ANUHPHR share price?
The 52-week high of ANUHPHR share price is ₹114.90 and the 52-week low is ₹69.27. These values are updated daily from NSE/BSE price data.
What factors affect the Anuh Pharma Ltd share price?
Key factors influencing ANUHPHR share price include quarterly earnings growth (Sales Growth: 12.01%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Anuh Pharma Ltd a good stock for long-term investment?
Anuh Pharma Ltd shows a 5-year Profit Growth of 25.58% and an ROE of 13.41%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in ANUHPHR shares.
How does Anuh Pharma Ltd compare with its industry peers?
Anuh Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare ANUHPHR share price P/E of 20.71x and ROE of 13.41% against the industry averages to determine competitive standing.
What is the P/E ratio of ANUHPHR and what does it mean?
ANUHPHR share price has a P/E ratio of 20.71x compared to the industry average of 31.77x. Investors pay ₹21 for every ₹1 of annual earnings.
How is ANUHPHR performing according to Bull Run's analysis?
ANUHPHR has a Bull Run fundamental score of 63.9/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ANUHPHR belong to?
ANUHPHR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Anuh Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for ANUHPHR?
ANUHPHR has an ROE of 13.41%, which shows decent profitability but room for improvement. ROE measures how efficiently Anuh Pharma Ltd generates profits from shareholders capital.
How is ANUHPHR debt-to-equity ratio and what does it indicate?
ANUHPHR has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is ANUHPHR dividend yield and is it a good dividend stock?
ANUHPHR offers a dividend yield of 1.88%, meaning you receive ₹1.88 annual dividend for every ₹100 invested in Anuh Pharma Ltd shares.
How has ANUHPHR share price grown over the past 5 years?
ANUHPHR has achieved 5-year growth rates of: Sales Growth 16.60%, Profit Growth 25.58%, and EPS Growth 25.58%.
What is the promoter holding in ANUHPHR and why does it matter?
Promoters hold 71.82% of ANUHPHR shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Anuh Pharma Ltd.
What is ANUHPHR market capitalisation category?
ANUHPHR has a market capitalisation of ₹802 crores, placing it in the Small-cap category.
How volatile is ANUHPHR stock?
ANUHPHR has a beta of N/A. A beta > 1 suggests the Anuh Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ANUHPHR operating profit margin trend?
ANUHPHR has a 5-year average Operating Profit Margin (OPM) of 10.23%, indicating the company's operational efficiency.
How is ANUHPHR quarterly performance?
Recent quarterly performance shows Anuh Pharma Ltd YoY Sales Growth of 12.01% and YoY Profit Growth of -49.40%.
What is the institutional holding pattern in ANUHPHR?
ANUHPHR has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Anuh Pharma Ltd stock.